PeopleBio, Inc. (KOSDAQ: 304840)
South Korea
· Delayed Price · Currency is KRW 3,160.00
-90.00 (-2.77%)
Dec 19, 2024, 2:34 PM KST
PeopleBio Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Operating Revenue | 4,373 | 4,453 | 4,445 | 577.08 | 507.85 |
| Other Revenue | -0 | - | - | 0 | - |
| Revenue | 4,373 | 4,453 | 4,445 | 577.08 | 507.85 |
| Revenue Growth (YoY) | 7.27% | 0.18% | 670.22% | 13.63% | - |
| Cost of Revenue | 3,146 | 3,077 | 3,115 | 1,365 | 664.06 |
| Gross Profit | 1,227 | 1,376 | 1,330 | -787.66 | -156.2 |
| Selling, General & Admin | 9,318 | 10,370 | 8,692 | 3,728 | 2,058 |
| Research & Development | 3,780 | 5,160 | 3,390 | 2,119 | 1,891 |
| Other Operating Expenses | 271.92 | 277.62 | 176.91 | 130.17 | 52.72 |
| Operating Expenses | 14,237 | 16,623 | 13,027 | 6,448 | 4,398 |
| Operating Income | -13,010 | -15,248 | -11,697 | -7,236 | -4,554 |
| Interest Expense | -387.65 | -2,399 | -2,979 | -1,134 | -24.83 |
| Interest & Investment Income | 266.36 | 376.99 | 533.49 | 98.51 | 37.47 |
| Earnings From Equity Investments | -916.85 | -934.89 | -835.96 | -380.5 | - |
| Currency Exchange Gain (Loss) | -0.26 | -34.87 | 15.67 | -1.9 | 1.91 |
| Other Non Operating Income (Expenses) | 1,476 | 2,277 | -58.18 | 3,706 | 149.62 |
| EBT Excluding Unusual Items | -12,573 | -15,962 | -15,020 | -4,947 | -4,390 |
| Gain (Loss) on Sale of Investments | -288.75 | -395.43 | - | - | - |
| Gain (Loss) on Sale of Assets | - | - | 17.65 | 5.17 | 6.9 |
| Other Unusual Items | -892.06 | -1,025 | - | - | - |
| Pretax Income | -13,754 | -17,382 | -15,003 | -4,942 | -4,383 |
| Earnings From Continuing Operations | -13,754 | -17,382 | -15,003 | -4,942 | -4,383 |
| Minority Interest in Earnings | 1,441 | 1,348 | 699.7 | 244.85 | - |
| Net Income | -12,313 | -16,035 | -14,303 | -4,697 | -4,383 |
| Net Income to Common | -12,313 | -16,035 | -14,303 | -4,697 | -4,383 |
| Shares Outstanding (Basic) | 21 | 17 | 15 | 14 | 12 |
| Shares Outstanding (Diluted) | 21 | 17 | 15 | 16 | 12 |
| Shares Change (YoY) | 41.85% | 13.30% | -8.80% | 32.18% | - |
| EPS (Basic) | -574.23 | -967.45 | -977.75 | -340.35 | -361.19 |
| EPS (Diluted) | -574.23 | -967.45 | -978.00 | -457.08 | -361.19 |
| Free Cash Flow | -13,265 | -17,001 | -15,242 | -8,188 | -3,652 |
| Free Cash Flow Per Share | -618.66 | -1025.76 | -1041.91 | -510.46 | -300.93 |
| Gross Margin | 28.06% | 30.90% | 29.92% | -136.49% | -30.76% |
| Operating Margin | -297.54% | -342.42% | -263.16% | -1253.81% | -896.78% |
| Profit Margin | -281.60% | -360.10% | -321.79% | -813.94% | -863.09% |
| Free Cash Flow Margin | -303.38% | -381.80% | -342.91% | -1418.84% | -719.10% |
| EBITDA | -11,326 | -13,683 | -10,415 | -6,501 | -4,270 |
| EBITDA Margin | -259.03% | - | -234.32% | - | - |
| D&A For EBITDA | 1,684 | 1,565 | 1,282 | 734.08 | 284.48 |
| EBIT | -13,010 | -15,248 | -11,697 | -7,236 | -4,554 |
| EBIT Margin | -297.54% | - | -263.16% | - | - |
| Advertising Expenses | - | 2,905 | 2,879 | 223.74 | 51.5 |
Source: S&P Capital IQ. Standard template. Financial Sources.